Financial Performance - The company's main business revenue continues to grow, while unconventional business revenue has declined significantly due to external environment and market demand changes [4]. - The net profit for the reporting period has decreased noticeably compared to the same period last year, attributed to substantial investments in subsidiaries and business expansion with delayed returns [4]. - The company's operating revenue for 2024 was ¥613,671,517.05, a decrease of 5.06% compared to ¥646,388,500.38 in 2023 [19]. - The net profit attributable to shareholders for 2024 was ¥121,927,677.07, down 53.13% from ¥260,131,747.68 in 2023 [19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,541,030.64, a decline of 78.27% from ¥168,156,726.17 in 2023 [19]. - The cash flow from operating activities for 2024 was ¥113,733,802.50, a significant drop of 64.74% compared to ¥322,564,042.97 in 2023 [19]. - The total assets at the end of 2024 were ¥6,054,708,956.79, representing an 8.27% decrease from ¥6,600,678,429.33 at the end of 2023 [19]. - The net assets attributable to shareholders at the end of 2024 were ¥5,772,912,131.96, down 9.33% from ¥6,366,982,288.85 at the end of 2023 [19]. - The basic earnings per share for 2024 were ¥0.9530, a decrease of 52.67% from ¥2.0134 in 2023 [19]. - The weighted average return on equity for 2024 was 1.97%, down 2.14% from 4.11% in 2023 [19]. - The company reported a total of ¥85,386,646.43 in non-recurring gains for 2024, compared to ¥91,975,021.51 in 2023 [25]. Business Strategy and Operations - The report indicates that the company will continue to focus on its core business of biological reagent products and services [4]. - The company operates in the life sciences sector, providing a "one-stop" procurement channel for biological reagents and technical services [28]. - The company has developed over 75,000 types of biological reagents, including more than 9,300 recombinant proteins and nearly 15,000 antibodies, catering to various fields of life science research [45]. - The company completed the acquisition of SignalChem Biotech Inc., a Canadian enzyme protein manufacturer, enhancing its product range and global business layout [37]. - The company has established subsidiaries in regions such as Suzhou, Taizhou, the United States, Europe, and Japan, improving local service support capabilities [36]. - The company serves over 10,000 cumulative customers across more than 90 countries and regions, covering major developed countries globally [44]. - The company has built a complete biological reagent R&D technology platform, significantly enhancing its research and development efficiency [44]. - The company focuses on high-quality biological reagents and technical services for global pharmaceutical R&D enterprises and life science research institutions [45]. - The company has a strong emphasis on local support, establishing logistics and customer service teams to enhance communication and reduce response times [36]. - The company has developed several unique high-difficulty G protein-coupled receptor products to meet the demands of antibody and cell therapy drug development [66]. Research and Development - The company maintains a high investment in R&D and technology innovation, continuously transforming technological achievements into a series of reagent products to meet customer needs [55]. - The company increased its R&D personnel to 269 in 2024, up 8.47% from 248 in 2023, with a notable increase in PhD holders by 46.67% [86]. - R&D investment reached approximately ¥91.21 million in 2024, representing 14.86% of total revenue, an increase from 13.53% in 2023 [86]. - The company aims to enhance its recombinant protein product development to address emerging viral threats, indicating a strategic focus on infectious disease solutions [84]. - The company plans to develop high-quality protein and antibody products for diagnostic reagents, leveraging its existing R&D capabilities in recombinant proteins and antibodies [120]. - The company aims to expand its market for dry powder culture media, which has seen increasing demand due to the growth of the biopharmaceutical industry [120]. Market and Competition - The company faces risks such as intensified international trade friction and increased industry competition, which may impact future performance [5]. - The market for biological reagents is becoming more concentrated, with industry consolidation trends increasing due to heightened competition [37]. - The company reported that unconventional business generated revenue of 54.19 million yuan, accounting for 8.83% of total revenue, indicating potential risks due to market demand fluctuations [130]. - The company faces risks from intensified industry competition, which may affect its market share and profitability if it cannot enhance its technological reserves and product quality [129]. - The company is at risk of core technology leakage and talent loss, which could undermine its competitive edge and market position [134]. Governance and Management - The company held three shareholder meetings in 2024, ensuring equal voting rights for all shareholders, particularly minority shareholders [140]. - The board of directors was reduced from 9 to 7 members, with 4 non-independent directors and 3 independent directors [142]. - The company conducted 6 board meetings in 2024, adhering strictly to legal and regulatory requirements [142]. - The supervisory board held 5 meetings in 2024, effectively overseeing major company matters and ensuring compliance [143]. - The company has established independent financial management systems, allowing for autonomous financial decision-making [151]. - The company maintains a complete and independent business system, capable of setting and achieving operational goals without external influence [147]. - The company has implemented a performance evaluation and incentive mechanism for its senior management, ensuring transparency in the hiring process [144]. - The company has a clear asset ownership structure, with no instances of asset occupation by shareholders or related parties [149]. - The company has established a robust information disclosure system to ensure timely and accurate communication with all stakeholders [145]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions and has completed environmental impact assessments for existing operations [196]. - The company is committed to social responsibility, focusing on high-quality reagent and service support for life sciences research and biopharmaceutical innovation [200]. - There were no major environmental accidents reported, and the company complied with relevant environmental laws and regulations [195]. - The company has developed an emergency response plan for environmental incidents and conducts regular drills [197]. - The company has established a self-monitoring plan for pollution emissions in accordance with regulatory requirements [198]. Employee Management - The total number of employees at the end of the reporting period is 1,021, with 691 from the parent company and 330 from major subsidiaries [178]. - The employee composition includes 547 technical personnel, 256 sales personnel, and 99 production personnel [178]. - The company has a training program that includes both internal and external training to enhance employee skills and corporate culture [180]. - The company has no retired employees requiring expense coverage, indicating a focus on current workforce management [178]. Financial Management - The company has a rigorous quality control system, ensuring product quality and stability through various detection methods, which helps to expand its customer base [57]. - The company utilizes a procurement model that includes regular supplier evaluations and a three-way bidding process to control procurement risks [48]. - The company has a production model that allows for dynamic adjustments based on market demand and order situations, ensuring efficient production planning [49]. - The company has established a comprehensive quality management model, obtaining certifications such as ISO9001 and GMP compliance [52]. - The company has maintained effective internal financial reporting controls as of December 31, 2024, according to the internal control audit report [192]. - The internal control audit report received a standard unqualified opinion from the accounting firm [192].

义翘神州（301047）公告，2024年营业收入6.14亿元，同比下降5.06%。归属于上市公司股东的净利润 1.22亿元，同比下降53.13%。公司经本次董事会审议通过的利润分配预案为：以1.22亿股为基数，向全 体股东每10股派发现金红利10元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

证券代码：301047 证券简称：义翘神州 公告编号：2025-003 北京义翘神州科技股份有限公司 关于全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）的全资子公司义翘神 州（泰州）科技有限公司（以下简称"义翘泰州"）于近日收到江苏省科学技术 厅、江苏省财政厅、国家税务总局江苏省税务局联合颁发的《高新技术企业证书》， 具体情况如下： 企业名称：义翘神州（泰州）科技有限公司 1 证书编号：GR202432007724 发证时间：2024 年 12 月 16 日 有效期：三年 根据《中华人民共和国企业所得税法》等有关规定，义翘泰州自通过高新技 术企业认定后连续三年（即 2024 年至 2026 年）可享受国家关于高新技术企业的 相关税收优惠政策，即按 15%的税率缴纳企业所得税。本次取得高新技术企业证 书不会对公司 2024 年度财务状况和经营业绩产生重大影响，敬请广大投资者注 意投资风险。 特此公告。 北京义翘神州科技股份有限公司董事会 2025 年 2 月 20 日 ...

证券代码：301047 证券简称：义翘神州 公告编号：2025-002 北京义翘神州科技股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 7 月 13 日出具的《关于同意北京义 翘神州科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕2364 号），北京义翘神州科技股份有限公司（以下简称"公司"）首次公开发行人民币 普通股（A 股）1,700 万股，每股面值 1 元，每股发行价为人民币 292.92 元，募 集资金总额为人民币 4,979,640,000.00 元，扣除发行费用（不含税）人民币 255,885,733.88 元，募集资金净额为人民币 4,723,754,266.12 元。上述募集资金已 全部到位，致同会计师事务所（特殊普通合伙）进行了审验，并出具了致同验字 （2021）第 110C000555 号《验资报告》。 二、募集资金存放和管理情况 为了规范募集资金的管理和使用，保护投资者的利益，根据《深圳证券交易 所创业板股票上 ...

Financial Performance - The estimated net profit attributable to shareholders for 2024 is projected to be between 117 million and 125 million CNY, representing a decrease of 51.95% to 55.02% compared to the previous year's profit of 260.13 million CNY [3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 32 million and 40 million CNY, reflecting a decline of 76.21% to 80.97% from the previous year's profit of 168.16 million CNY [3]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 85 million CNY, down from 91.98 million CNY in the previous year [6]. Business Focus and Revenue - The company continues to focus on its core business of biological reagent products and services, with conventional business revenue maintaining steady growth [5]. - Non-conventional business revenue has significantly declined due to external environment changes and market demand fluctuations [5]. - The company has made substantial investments in business expansions in Suzhou, Taizhou, Canada (SCB), and the U.S. (C4B), which have resulted in delayed returns [5]. Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report [7].

证书编号：GR202411003578 发证时间：2024 年 10 月 29 日 有效期：三年 证券代码：301047 证券简称：义翘神州 公告编号：2024-069 北京义翘神州科技股份有限公司 关于公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于近日收到北京市科 学技术委员会、北京市财政局、国家税务总局北京市税务局联合颁发的《高新技 术企业证书》，具体情况如下： 企业名称：北京义翘神州科技股份有限公司 北京义翘神州科技股份有限公司董事会 2024 年 12 月 19 日 1 本次高新技术企业认定系原证书有效期满后所进行的重新认定。根据《中华 人民共和国企业所得税法》等有关规定，公司通过高新技术企业重新认定后连续 三年（即 2024 年至 2026 年）可继续享受国家关于高新技术企业的相关税收优惠 政策，即按 15%的税率缴纳企业所得税。公司 2024 年度已按照 15%的企业所得 税税率进行纳税申报及预缴，本次取得高新技术企业证书不影响公司 2024 年度 的相关财务数 ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-068 北京义翘神州科技股份有限公司 关于控股股东、实际控制人持股比例变动超过 1%的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，北京义翘神州科技股份有限公司（以下简称"公 司"）于 2024 年 12 月 6 日在中国证券登记结算有限责任公司深圳分公司办理了 4,533,890 股回购股份注销事宜，公司总股本由 126,170,632 股减少至 121,636,742 股。因前述事项，控股股东拉萨爱力克投资咨询有限公司及实际控制人、董事长 谢良志先生合计持有的公司股份比例被动增加 2.01%。现将有关情况公告如下： | 1.基本情况 | | | | | | --- | --- | --- | --- | --- | | 信息披露义务人 | 拉萨爱力克投资咨询有限公司、谢良志 | | | | | 住所 | 拉萨爱力克投资咨询有限公司：西藏拉萨市经济技术开发区林琼岗东 一路7号A座705房0 ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-067 北京义翘神州科技股份有限公司 关于 2024 年第二期回购公司股份注销完成 暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、北京义翘神州科技股份有限公司（以下简称"公司"）本次注销回购股份 4,533,890 股，占注销前公司总股本的 3.59%。本次注销完成后，公司总股本由 126,170,632 股减少至 121,636,742 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次 4,533,890 股回购股份注销事宜已于 2024 年 12 月 6 日办理完成。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，现就本次回购公司股份注销完成暨股份变动情 况公告如下： 一、本次回购股份的审批及实施情况 公司分别于 2024 年 7 月 16 日、2024 年 8 月 1 日召开第二届董事会第十一 次会议和 2024 年第二次临时股东大会，审议通过了《关于 2024 年第二期回购公 司股 ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-066 北京义翘神州科技股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 北京义翘神州科技股份有限公司（以下简称"公司"）于近日收到公司控股 股东拉萨爱力克投资咨询有限公司（以下简称"爱力克"）的通知，获悉其所持 有公司部分股份办理了质押业务，具体事项如下： | 股东 名称 | 是否为控 股股东或 第一大股 | 本 次 质 押 | 占其所 持股份 | 占公司 总股本 | 是否 为限 | 是否 为补 充质 | 质押起始 日 | 质押到 期日 | 质权人 | 质押用 途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一 | 数量（股） | 比例 | 比例 | 售股 | | | | | | | | | | | | | 押 | | | | | | | 致行动人 | | | | | | | | | | | 爱力克 | 是 | 15, ...

证券代码：301047 证券简称：义翘神州 公告编号：2024-065 北京义翘神州科技股份有限公司 关于 2024 年第二期回购公司股份实施完成 暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）分别于 2024 年 7 月 16 日、2024 年 8 月 1 日召开第二届董事会第十一次会议和 2024 年第二次临时股 东大会，审议通过了《关于 2024 年第二期回购公司股份方案的议案》，同意公 司使用自有资金以集中竞价方式回购股份用于注销并减少公司注册资本。本次回 购资金总额为不低于人民币 20,000 万元且不超过人民币 40,000 万元（均包含本 数），回购价格不超过人民币 90 元/股（含）。具体回购股份的数量以回购结束 时实际回购的股份数量为准。本次回购实施期限自公司股东大会审议通过本次回 购股份方案之日起不超过 12 个月。具体内容详见公司于 2024 年 7 月 17 日、2024 年 8 月 1 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于 2024 年第 ...